Sensus Healthcare, Inc. (SRTS)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $2.89
- As of
Kresmion compiles this page from SRTS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Sensus Healthcare, Inc. (SRTS): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-14.
See the full SRTS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SRTS on one page. Preview it with sample data, then open it live with a free account.
Preview the SRTS dossierActive signals for SRTS
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 41.2%, EPS $-0.18 vs $-0.1275 estimate
- lowEARNINGS_MISS
Q2-2025: EPS $-0.06 vs $0.0265 estimate, -0.09 on a near-zero consensus
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 38.1% - EPS $-0.06 vs $-0.0969 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 166.1% - EPS $-0.19 vs $-0.0714 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 25.5% - EPS $-0.16 vs $-0.1275 estimate
FREE, NO ACCOUNT
Every signal on SRTS, as it fires
New filings, 13F moves and cross asset signals on SRTS land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SRTS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 81728J109 · 2026Q2 | $732K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SRTS
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SRTS against its peers
SRTS's operating margin of -37.5% ranks in the 69th percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | SRTS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 27.5M USD | 32.0M USD | 48 | 23 |
| Gross margin | 43.2% | 52.7% | 33 | 19 |
| Operating margin | -37.5% | -59.3% | 69 | 23 |
| Net margin | -28.1% | -68.3% | 73 | 23 |
| Return on equity | -16.0% | -85.0% | 74 | 20 |
| 1 year | -10.0% | -33.6% | 73 | 19 |
Peers (23): SNWV, XTNT, TELA, RPID, COCH, MDAI, NNOX, POSC, MDNC, QTI, ARAY, CVRX, MYO, ELUT, NSYS, OM, ZOMDF, LUNG, SERA, ITOC, LNSR, NSPR, HYPR. Left out: TLTFF (no annual filing), RTGN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SRTS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SRTS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SRTS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.